{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:30:46Z","timestamp":1787761846293,"version":"build-2784847793"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Alcohol use disorders (AUDs) are characterized by excessive alcohol consumption, negatively impacting health, social life, and economic status. Globally, AUD contributes to significant disease burden, causing millions deaths annually. Despite the availability of treatments, relapse rates remain high. Naltrexone and acamprosate, two FDA-approved anticraving agents, are widely used to prevent relapse. However, comparative studies in Indian populations are limited, prompting this study to assess the efficacy of these drugs in treating AUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim:<\/jats:title>\n                    <jats:p>This study aimed to compare the effectiveness of naltrexone and acamprosate as anticraving agents in treating AUD, evaluating the time to first drink (lapse) and time to relapse among patients using either medication at 1 and 3 months. It also assessed the correlation between baseline severity of AUD and the efficacy of naltrexone and acamprosate as anticraving agents, as well as compared demographic and clinical variables between the two treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A prospective observational study was conducted on 70 patients diagnosed with AUD, divided into two groups: naltrexone (n = 35) and acamprosate (n = 35). Patients were assessed using the Obsessive Compulsive Drinking Scale (OCDS) and followed for 3 months to evaluate craving intensity, time to first drink, and relapse rates. The Quality of Life Scale (QOLS) and Clinical Global Impression (CGI) were used to assess treatment impact.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Both groups were comparable at baseline. At 3 months, naltrexone patients had higher abstinence rates (63.64%) compared with acamprosate (34.68%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.018). Naltrexone also significantly extended the time to first drink and relapse compared to acamprosate.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Naltrexone demonstrated superior efficacy in maintaining abstinence and reducing relapse rates in AUD patients compared to acamprosate. These findings suggest that naltrexone may be more effective for long-term treatment in the Indian context.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ipj.ipj_413_24","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T07:00:14Z","timestamp":1744959614000},"page":"97-102","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A comparative study evaluating the efficacy of naltrexone versus acamprosate as anticraving agents in alcohol use disorder"],"prefix":"10.4103","volume":"34","author":[{"given":"Samant","family":"Singh","sequence":"first","affiliation":[{"name":"All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakhan","family":"Kataria","sequence":"additional","affiliation":[{"name":"Smt. B. K. Shah Medical Institute and Research Centre, Vadodara, Sumandeep Vidyapeeth University, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohd Rashid","family":"Alam","sequence":"additional","affiliation":[{"name":"All India Institute of Medical Sciences, Gorakhpur, Uttar Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"issue":"9","key":"R3-20260423","first-page":"49","article-title":"Alcohol consumption in India\u2013 An epidemiological review","volume":"28","author":"Eashwar","year":"2020","journal-title":"J Fam Med Prim Care"},{"key":"R4-20260423","first-page":"627","article-title":"A comparative study of factors associated with relapse in alcohol dependence and opioid dependence","volume":"39","author":"Kadam","year":"2017","journal-title":"Indian J Psychol Med"},{"key":"R5-20260423","first-page":"355","article-title":"The neurobiology of alcohol craving and relapse","volume":"125","author":"Seo","year":"2014","journal-title":"Handb Clin Neurol"},{"key":"R6-20260423","first-page":"167","article-title":"Pharmacotherapy for alcohol dependence: Anticraving medications for relapse prevention","volume":"47","author":"Jung","year":"2006","journal-title":"Yonsei Med J"},{"key":"R7-20260423","first-page":"105","article-title":"Anticraving therapy for alcohol use disorder: A clinical review","volume":"38","author":"Shen","year":"2018","journal-title":"Neuropsychopharmacol Rep"},{"key":"R8-20260423","first-page":"572","article-title":"Adherence across FDA-Approved medications for alcohol use disorder in a veterans administration population","volume":"80","author":"Walker","year":"2019","journal-title":"J Stud Alcohol Drugs"},{"key":"R9-20260423","first-page":"542","article-title":"Combined therapy: What does acamprosate and naltrexone combination tell us?","volume":"39","author":"Kiefer","year":"2004","journal-title":"Alcohol"},{"key":"R10-20260423","first-page":"1438","article-title":"Comparison of acamprosate and placebo in long-term treatment of alcohol dependence","volume":"347","author":"Whitworth","year":"1996","journal-title":"The Lancet"},{"key":"R11-20260423","first-page":"881","article-title":"Naltrexone and coping skills therapy for alcohol dependence. A controlled study","volume":"49","author":"O'Malley","year":"1992","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"R12-20260423","first-page":"419","article-title":"Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment","volume":"36","author":"Rubio","year":"2001","journal-title":"Alcohol Alcohol"},{"issue":"1","key":"R12-20260423","first-page":"105","article-title":"Erratum","volume":"37","year":"2002","journal-title":"Alcohol Alcohol"},{"key":"R13-20260423","first-page":"92","article-title":"Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: A double-blind, placebo-controlled study","volume":"60","author":"Kiefer","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R14-20260423","first-page":"419","article-title":"Naltrexone versus acamprosate: One year follow-up of alcohol dependence treatment","volume":"36","author":"Rubio","year":"2001","journal-title":"Alcohol"},{"key":"R15-20260423","first-page":"466","article-title":"A systematic review of naltrexone for attenuating alcohol consumption in women with alcohol use disorders (AUD)","volume":"41","author":"Canidate","year":"2017","journal-title":"Alcohol Clin Exp Res"},{"key":"R16-20260423","first-page":"211","article-title":"Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: A systematic review","volume":"7","author":"Sawicka","year":"2017","journal-title":"Ther Adv Psychopharmacol"},{"key":"R17-20260423","first-page":"1758","article-title":"Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial","volume":"156","author":"Anton","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R18-20260423","first-page":"1335","article-title":"Efficacy of naltrexone and acamprosate for alcoholism treatment: A meta-analysis","volume":"25","author":"Kranzler","year":"2001","journal-title":"Alcohol Clin Exp Res"}],"container-title":["Industrial Psychiatry Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ipj.ipj_413_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:09:28Z","timestamp":1787760568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ipj.ipj_413_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/ipj.ipj_413_24","relation":{},"ISSN":["0972-6748","0976-2795"],"issn-type":[{"value":"0972-6748","type":"print"},{"value":"0976-2795","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-10-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}